Holen Sie sich die Stockscreener-App
1.72
1.17%
-0.01
Schlusskurs vom Vortag:
$1.71
Offen:
$1.72
24-Stunden-Volumen:
7,657
Relative Volume:
0.01
Marktkapitalisierung:
$83.30M
Einnahmen:
$42,000
Nettoeinkommen (Verlust:
$-12.38M
KGV:
-6.53
EPS:
-0.2634
Netto-Cashflow:
$-9.61M
1W Leistung:
-4.52%
1M Leistung:
+43.22%
6M Leistung:
+6.29%
1J Leistung:
-7.65%
1-Tages-Spanne:
$1.68
$1.72
1-Wochen-Bereich:
$1.60
$1.90
52-Wochen-Spanne:
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Firmenname
Entera Bio Ltd
Sektor
Branche
Telefon
972-2-532-7151
Adresse
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.69 | 87.24M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
515.11 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.07 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.51 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.50 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.78 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-22 | Eingeleitet | Aegis Capital | Buy |
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus - TradingView
Price to earnings forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to earnings forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to EBIT forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Price to book forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Entera Bio Ltd. Actuals & Estimates (HAM:5DT) - TradingView
ENTX Forecast — Price Target — Prediction for 2027 - TradingView
5DT Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback - Investing.com UK
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Entera Bio Ltd (ENTX) Institutional Confidence - TradingKey
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewswire Inc.
3 Promising Penny Stocks With Market Caps Under $600M - simplywall.st
Entera Bio Ltd (ENTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline - timothysykes.com
ENTX stock on track for best day in over 5 years — what’s driving the rally? - MSN
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? - Yahoo Finance
FDA backs Entera Bio’s 750-patient osteoporosis trial for EB613 - Stock Titan
With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For - TipRanks
Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback - marketscreener.com
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - The Manila Times
Entera Bio Receives Positive FDA Feedback on 12-Month - GlobeNewswire
Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
After Novo Nordisk's Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story? - Benzinga
Entera Bio Ltd (ENTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Ltd (ENTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entera Bio reports preclinical data for two oral peptide programs By Investing.com - Investing.com South Africa
Entera Bio reports preclinical data for two oral peptide programs - Investing.com UK
Entera Reports Robust Preclinical Data for EB612 (Oral - GlobeNewswire
Experimental oral hormone pills aim at hypoparathyroidism, obesity - Stock Titan
Entera Bio Ltd. (ENTX) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Entera Bio presents Phase 1 data on single-tablet EB613 By Investing.com - Investing.com South Africa
Entera Bio presents Phase 1 data on single-tablet EB613 - Investing.com
ENDO 2026 Oral Presentation Highlights Comparative Clinical - GlobeNewswire
Entera Bio (ENTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesMargin Expansion Trends - newsline.com
Entera Bio (ENTX) Slides 4.1% as Selling Pressure Tests Key Support at $1.11Long Term Entry Picks - newsline.com
ENTX Q1 2026 Earnings: Surprise EPS Beat as Operating Loss NarrowsEarnings Beat Alert - newsline.com
ENTX | Entera Bio Ltd. Ordinary Executive Compensation - Quiver Quantitative
Entera Bio (ENTX) Holds Steady at $1.22 as Stock Consolidates Near SupportElliott Wave Count - newsline.com
[ARS] Entera Bio Ltd. SEC Filing - Stock Titan
Finanzdaten der Entera Bio Ltd-Aktie (ENTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Entera Bio Ltd-Aktie (ENTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
1.95%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):